Naltrexone treatment of tardive dyskinesia in patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 24, Issue 4, 2004, Pages 441-445

  Wonodi, Ikwunga ^a   Adami, Helene ^a   Sherr, Jay ^a   Avila, Matthew ^a   Hong, L Elliot ^a   Thaker, Gunvant K ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; CLONAZEPAM; ENKEPHALIN; NALTREXONE; OPIATE ANTAGONIST; OPIATE PEPTIDE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DYSKINESIA; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NAUSEA; NERVE CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SACCADIC EYE MOVEMENT; SCHIZOPHRENIA; SEDATION; TARDIVE DYSKINESIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CLONAZEPAM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; SCHIZOPHRENIA;

EID: 3242696064     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000132440.27854.44     Document Type: Article

References (32)

1. Halliday J, Farrington S, Macdonald S, et al. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-Year review. Br J Psychiatry. 2002;181:422-427.
2. Emsley RA, Oosthuizen PP, Joubert AF, et al. Treatment of schizophrenia in low-income countries. Int J Neuropsychopharmacol. 1999;2:321-325.
3. Albin RL, Aldridge JW, Young AB, et al. Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivity. Brain Res. 1989;491:185-188.
4. De Long MR. Primate models of movement disorders of basal ganglia origin [review]. Trends Neurosci. 1990;13:281-285.
5. Iakimovskii AF, Bobrova IV. Neuromotor dyskinesia occurring during repeated injections of enkephalins into the rat striatum. Patol Fiziol Eksp Ter. 1991:20-22.
6. Egan MF, Hurd Y, Hyde TM, et al. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse. 1994;18:178-189.
7. Stoessl AJ, Polanski E, Frydryszak H. The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. Mov Disord. 1993;8:445-452.
8. Cadet JL, Braun TL. Naltrexone inhibits the persistent spasmodic dyskinesia induced by chronic intraperitoneal administration of iminodipropionitrile (IDPN). Neuropeptides. 1986;8:87-91.
9. Pollock J, Kometsky C. Naloxone prevents and blocks the emergence of neuroleptic-mediated oral stereotypic behaviors. Neuropsychopharmacology. 1991;4:245-249.
10. McCormick SE, Stoessl AJ. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience. 2002;112:851-859.
11. Volavka J, Anderson B, Koz G. Naloxone and naltrexone in mental illness and tardive dyskinesia. Ann NY Acad Sci. 1982;398:97-102.
12. Sandyk R, Snider SR. Naloxone and tardive dyskinesia. Biol Psychiatry. 1985;20:1335-1336.
13. Blum I, Munitz H, Shalev A, et al. Naloxone may be beneficial in the treatment of tardive dyskinesia. Clin Neuropharmacol. 1984;7:265-267.
14. Blum I, Nisipeanu PF, Roberts E. Naloxone in tardive dyskinesia. Psychopharmacology (Berl). 1987;93:538.
15. Rascol O, Fabre N, Blin O, et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord. 1994;9:437-440.
16. Manson AJ, Katzenschlager R, Hobart J, et al. High dose naltrexone for dyskinesias induced by levodopa. J Neurol Neurosurg Psychiatry. 2001;70:554-556.
17. Kurlan R, Majumdar L, Deeley C, et al. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. Ann Neurol. 1991;30:19-23.
18. Erenberg G, Lederman RJ. Naltrexone and Tourette's syndrome. Ann Neurol. 1992;31:574.
19. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia [letter]. Arch Gen Psychiatry. 1982;39:486-487.
20. Cassady SL, Thaker GK, Summerfelt A, et al. The Maryland Psychiatric Research Center scale for the characterization of involuntary movements. Psychiatry Res. 1997;70:21-37.
21. Overall J, Gorman D. The brief psychiatric rating scale in psychopharmacologic research. Psychol Res. 1961;30:19-23.
22. Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM III-R (SCID-P). 1989 New York, NY: Biometrics Research Department, New York State Psychiatric Institute.
23. Thaker GK, Ross DE, Cassady SL, et al. Saccadic eye movement abnormalities in relatives of patients with schizophrenia. Schizophr Res. 2000;45:235-244.
24. Levine G. A Guide to SPSS for Analysis of Variance. 1991 Hillsdale, NJ: Lawrence Erlbaum Assoc.
25. vanSteveninck AL, Verver S, Schoemaker HC, et al. Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers. Clin Pharmacol Ther. 1992;52:402-408.
26. Richens A, Mercer AJ, Jones DM, et al. Effects of zolpidem on saccadic eye movements and psychomotor performance: a double-blind, placebo controlled study in healthy volunteers. Br J Clin Pharmacol. 1993;36:61-65.
27. Kroboth PD, Folan MM, Bauer KS, et al. Do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course? J Clin PharmacoL 1998;38:337-346.
28. Masson GS, Mestre DR, Martineau F, et al. Lorazepam-induced modifications of saccadic and smooth-pursuit eye movements in humans: attentional and motor factors. Behav Brain Res. 2000;108:169-180.
29. Rodgers RJ, Randall J, Kelway B. Naloxone potentiates the depressant effect of chlordiazepoxide on spontaneous activity in mice. Neurosci Lett. 1985;58:97-100.
30. Fidecka S, Langwinski R. Effects of opioid antagonists on anticonvulsant and hypnotic activity of benzodiazepines. Pol J Pharmacol. 1996;48:409-414.
31. Eichenberger GC, Ribeiro SJ, Osaki MY, et al. Neuroanatomical and psychopharmacological evidence for interaction between opioid and GABAergic neural pathways in the modulation of fear and defense elicited by electrical and chemical stimulation of the deep layers of the superior colliculus and dorsal periaqueductal gray matter. Neuropharmacology. 2002;42:48-59.
32. Rozsa KS, Rubakhin SS, Szucs A, et al. Met-enkephalin and morphiceptin modulate a GABA-induced inward current in the CNS of Lymnaea stagnalis L. Gen Pharmacol. 1996;27:1337-1345.